FDA Committee Votes in Favor of Dyax Lead Drug for Rare Blood Disease

An FDA advisory committee recommended approval of Cambridge, MA-based Dyax’s lead drug candidate, ecallantide, to treat severe attacks of a rare blood disease known as hereditary angioedema, according to an FDA spokeswoman.
Xconomy